BCR and acute lymphoblastic leukemia: However, Dasatinib, an inhibitor of the constitutively active tyrosine kinase BCR-ABL, is already used for treating Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in cases of resistance or intolerance to prior therapies.